Arcturus Therapeutics (ARCT)

• Market cap: $348M
• 1 day: 0.00%
• 5 days: 1.42%
• 1 month: 21.06%
• 3 months: -23.87%
• 6 months: -32.95%
• Year to date: -24.90%
• 1 year: -51.86%
• 5 years: -61.06%
• 10 years: 128.52%
• Sector: Healthcare
• Industry: Biotechnology

About: Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.

Employees: 176

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

20% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 46

1.26% more ownership

Funds ownership: 97.1% [Q3] → 98.36% (+1.26%) [Q4]

1% less call options, than puts

Call options by funds: $2.94M | Put options by funds: $2.98M

11% less funds holding

Funds holding: 164 [Q3] → 146 (-18) [Q4]

26% less capital invested

Capital invested by funds: $609M [Q3] → $452M (-$157M) [Q4]

52% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 31

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $50 290% upside
• Avg. target: $59 363% upside
• High target: $68 430% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Ed Arce 39% 1-year accuracy 59 / 151 met price target	368% upside $60	Buy Reiterated	10 Apr 2025
Canaccord Genuity Whitney Ijem 32% 1-year accuracy 14 / 44 met price target	430% upside $68	Buy Maintained	10 Mar 2025
Wells Fargo Yanan Zhu 13% 1-year accuracy 2 / 16 met price target	290% upside $50	Overweight Maintained	7 Mar 2025